Insitro

Insitro is a drug discovery and development company that uses machine learning and data to identify and develop new medicines. The company's platform integrates in vitro cellular data produced in its labs with human clinical data to help redefine disease. Insitro's pipeline includes wholly-owned and partnered therapeutic programs in metabolism, oncology, and neuroscience.

Ignota Labs is a technology company focused on rescuing failing drugs and bringing new life to abandoned projects, ultimately providing hope to patients. The company utilizes a proprietary AI model, SAFEPATH, which applies deep learning to bioinformatics and cheminformatics datasets to solve drug safety issues. Ignota Labs aims to identify promising drug targets, address safety problems in clinical trials, and accelerate the delivery of therapeutically effective drugs to patients.

Recursion is a techbio company that uses artificial intelligence to accelerate drug discovery. The company's platform combines hardware, software, and data to create a more efficient and effective drug discovery process. Recursion has a broad pipeline of drug candidates in development, and it has partnered with several leading pharmaceutical companies. The company is headquartered in Salt Lake City, Utah.

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques. The company's proprietary AI platform is used to identify, re-innovate, and develop potential new therapies. BioXcel Therapeutics has a pipeline of product candidates in various stages of development, including BXCL501 for agitation in dementia, BXCL701 for cocaine use disorder, and BXCL801 for acute suicidal ideation and behavior in patients with major depressive disorder.

neurons.bio is an AI application that offers a unique collection of over 100 AI agents designed for drug development, medicine, and life science research. These agents perform specific tasks efficiently, retrieve data from various sources, and provide insights to accelerate research processes. The platform aims to revolutionize drug discovery and development by integrating cutting-edge LLM technology with domain-specific agents, reducing research costs and time to clinic.

Genesis Therapeutics is an AI platform that leverages cutting-edge technology to revolutionize drug discovery and development processes. The platform integrates advanced algorithms and machine learning models to accelerate the identification of novel drug candidates and optimize their properties. By combining computational simulations with experimental data, Genesis Therapeutics offers a comprehensive solution to streamline the drug development pipeline and bring innovative therapies to market faster. The platform is designed to empower researchers and pharmaceutical companies with powerful tools for predicting drug-target interactions, optimizing molecular structures, and prioritizing lead compounds for further investigation.

JADBio is an automated machine learning (AutoML) platform designed to accelerate biomarker discovery and drug development processes. It offers a no-code solution that automates the discovery of biomarkers and interprets their role based on research needs. JADBio can parse multi-omics data, including genomics, transcriptome, metagenome, proteome, metabolome, phenotype/clinical data, and images, enabling users to efficiently discover insights for various conditions such as cancer, immune system disorders, chronic diseases, infectious diseases, and mental health. The platform is trusted by partners in precision health and medicine and is continuously evolving to disrupt drug discovery times and costs at all stages.

Owkin is a full-stack AI biotech company that integrates the best of human and artificial intelligence to deliver better drugs and diagnostics at scale. By understanding complex biology through AI, Owkin identifies new treatments, de-risks and accelerates clinical trials, and builds diagnostic tools to reduce time to impact for patients.

Deep Genomics is a company that uses artificial intelligence (AI) to develop RNA therapies for genetic diseases. The company's AI platform is designed to identify novel targets and evaluate thousands of possibilities to identify the best therapeutic candidates. Deep Genomics is currently developing BigRNA+, which will expand the number of mechanisms and genetic variants the company can pursue.

AiCure provides a patient-centric eClinical trial management platform that enhances drug development through improved medication adherence rates, more powerful analysis and prediction of treatment response using digital biomarkers, and reduced clinical tech burden. AiCure's solutions support traditional, decentralized, or hybrid trials and offer flexibility to meet the needs of various research designs.

VantAI is an AI application focused on generative AI-enabled drug discovery. Their mission is to unlock a new chapter in medicine by making protein interactions programmable. They have an integrated discovery platform with phase-shifting technologies designed to unlock the full potential of the proximity modulator modality. VantAI collaborates with industry leaders to build the future of therapeutic design. The company has launched Neo-1, the first AI model to rewire molecular interactions by unifying structure prediction and generation.

Beacon Biosignals provides an EEG neurobiomarker platform that is designed to accelerate clinical trials and enable new treatments for patients with neurological and psychiatric diseases. Their platform is powered by machine learning and a world-class clinico-EEG database, which allows them to analyze existing EEG data for insights into mechanisms, PK/PD, and patient stratification. This information can be used to guide further development efforts, optimize clinical trials, and enhance understanding of treatment efficacy.

Iambic Therapeutics is a cutting-edge AI-driven drug discovery platform that tackles the most challenging design problems in drug discovery, addressing unmet patient need. Its physics-based AI algorithms drive a high-throughput experimental platform, converting new molecular designs to new biological insights each week. Iambic's platform optimizes target product profiles, exploring multiple profiles in parallel to ensure that molecules are designed to solve the right problems in disease biology. It also optimizes drug candidates, deeply exploring chemical space to reveal novel mechanisms of action and deliver diverse high-quality leads.

Tempus is an AI-enabled precision medicine company that brings the power of data and artificial intelligence to healthcare. With the power of AI, Tempus accelerates the discovery of novel targets, predicts the effectiveness of treatments, identifies potentially life-saving clinical trials, and diagnoses multiple diseases earlier. Tempus's innovative technology includes ONE, an AI-enabled clinical assistant; NEXT, a tool to identify and close gaps in care; LENS, a platform to find, access, and analyze multimodal real-world data; and ALGOS, algorithmic models connected to Tempus's assays to provide additional insight.

Decode Health is an AI and analytics platform that accelerates precision healthcare by supporting healthcare teams in launching machine learning and advanced analytics projects. The platform collaborates with pharmaceutical companies to enhance patient selection, biomarker identification, diagnostics development, data asset creation, and analysis. Decode Health offers modules for biomarker discovery, patient recruitment, next-generation sequencing, data analysis, and clinical decision support. The platform aims to provide fast, accurate, and actionable insights for acute and chronic disease management. Decode Health's custom-built modules are designed to work together to solve complex data problems efficiently.

Freenome is a healthcare company that uses artificial intelligence and multiomics technology to detect cancer in its earliest stages through a simple blood draw. The company's mission is to make early cancer detection more accessible and affordable, and to improve the chances of successful treatment.

Genesis Therapeutics is an AI platform that leverages cutting-edge technology to revolutionize drug discovery and development processes. The platform integrates advanced algorithms and machine learning models to accelerate the identification of novel drug candidates and optimize their properties. By combining computational simulations with experimental data, Genesis Therapeutics offers a comprehensive solution to streamline the drug development pipeline and bring innovative therapies to market faster. The platform is designed to empower researchers and pharmaceutical companies with powerful tools for predicting drug-target interactions, optimizing molecular structures, and prioritizing lead compounds for further investigation.

JADBio is an automated machine learning (AutoML) platform designed to accelerate biomarker discovery and drug development processes. It offers a no-code solution that automates the discovery of biomarkers and interprets their role based on research needs. JADBio can parse multi-omics data, including genomics, transcriptome, metagenome, proteome, metabolome, phenotype/clinical data, and images, enabling users to efficiently discover insights for various conditions such as cancer, immune system disorders, chronic diseases, infectious diseases, and mental health. The platform is trusted by partners in precision health and medicine and is continuously evolving to disrupt drug discovery times and costs at all stages.

Synthace is a software and expertise platform designed for Discovery Biology Teams to streamline and optimize their experiments in assay development, media optimization, and purification process development. The platform offers software solutions, training, and on-site support from specialists to help scientists conduct experiments more efficiently and effectively. By leveraging multifactorial methods and automation, Synthace aims to accelerate drug discovery processes and deliver faster, definitive results.

Insitro is a drug discovery and development company that uses machine learning and data to identify and develop new medicines. The company's platform integrates in vitro cellular data produced in its labs with human clinical data to help redefine disease. Insitro's pipeline includes wholly-owned and partnered therapeutic programs in metabolism, oncology, and neuroscience.

Salt AI is a development engine tailored for life sciences organizations, aiming to accelerate advancements in the field by enabling faster adoption and utilization of AI technologies. The platform offers reliable and reproducible AI processes, optimized for speed and efficiency, and promotes transparency and collaboration within workflows. With a focus on supporting best-in-class life sciences research models, Salt AI empowers users to enhance their understanding of biological processes through flexible and performant AI solutions.

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques. The company's proprietary AI platform is used to identify, re-innovate, and develop potential new therapies. BioXcel Therapeutics has a pipeline of product candidates in various stages of development, including BXCL501 for agitation in dementia, BXCL701 for cocaine use disorder, and BXCL801 for acute suicidal ideation and behavior in patients with major depressive disorder.

Recursion is a techbio company that uses artificial intelligence to accelerate drug discovery. The company's platform combines hardware, software, and data to create a more efficient and effective drug discovery process. Recursion has a broad pipeline of drug candidates in development, and it has partnered with several leading pharmaceutical companies. The company is headquartered in Salt Lake City, Utah.

Atomwise is an AI-powered drug discovery company that uses machine learning to identify new small molecule medicines. The company's platform combines the power of convolutional neural networks with massive chemical libraries to discover new drug candidates. Atomwise has a portfolio of wholly owned and co-developed pipeline assets, and is backed by prominent investors.

JADBio is an automated machine learning (AutoML) platform designed to accelerate biomarker discovery and drug development processes. It offers a no-code solution that automates the discovery of biomarkers and interprets their role based on research needs. JADBio can parse multi-omics data, including genomics, transcriptome, metagenome, proteome, metabolome, phenotype/clinical data, and images, enabling users to efficiently discover insights for various conditions such as cancer, immune system disorders, chronic diseases, infectious diseases, and mental health. The platform is trusted by partners in precision health and medicine and is continuously evolving to disrupt drug discovery times and costs at all stages.

Cradle is a protein engineering platform that uses machine learning to design improved protein sequences. It allows users to import assay data, generate new sequences, test them in the lab, and import the results to improve the model. Cradle can be used to optimize multiple properties of a protein simultaneously, and it has been used by leading biotech teams to accelerate new and ongoing projects.

PubCompare is a powerful AI-powered tool that helps scientists search, compare, and evaluate experimental protocols. With over 40 million protocols in its database, PubCompare is the largest repository of trusted experimental protocols. PubCompare's AI-powered search features allow users to find similar protocols, highlight critical steps, and evaluate the reproducibility of protocols based on in-protocol citations. PubCompare is available from any computer and requires no download.

Insitro is a drug discovery and development company that uses machine learning and data to identify and develop new medicines. The company's platform integrates in vitro cellular data produced in its labs with human clinical data to help redefine disease. Insitro's pipeline includes wholly-owned and partnered therapeutic programs in metabolism, oncology, and neuroscience.

Deep Genomics is a company that uses artificial intelligence (AI) to develop RNA therapies for genetic diseases. The company's AI platform is designed to identify novel targets and evaluate thousands of possibilities to identify the best therapeutic candidates. Deep Genomics is currently developing BigRNA+, which will expand the number of mechanisms and genetic variants the company can pursue.

BenevolentAI is a leader in applying advanced AI to accelerate biopharma drug discovery blending science and technology with a focus on finding solutions for complex diseases. We empower both biopharmaceutical companies and our internal scientists to harness the full potential of data and AI to accelerate the next generation of scientific advances. We have built our AI-enabled drug discovery engine to drive a revolution in drug discovery. The Benevolent Platform™ unlocks the power of a vast biomedical data landscape to provide a multidimensional representation of human biology across all diseases. We believe this approach will improve the probability of clinical success, and help us deliver life-changing treatments to patients – because it matters.

XtalPi is a world-leading technology company driven by artificial intelligence (AI) and robotics to innovate in the fields of life sciences and new materials. Founded in 2015 at the Massachusetts Institute of Technology (MIT), the company is committed to realizing digital and intelligent innovation in the fields of life sciences and new materials. Based on cutting-edge technologies and capabilities such as quantum physics, artificial intelligence, cloud computing, and large-scale experimental robot clusters, the company provides innovative technologies, services, and products for global industries such as biomedicine, chemicals, new energy, and new materials.

Iambic Therapeutics is a cutting-edge AI-driven drug discovery platform that tackles the most challenging design problems in drug discovery, addressing unmet patient need. Its physics-based AI algorithms drive a high-throughput experimental platform, converting new molecular designs to new biological insights each week. Iambic's platform optimizes target product profiles, exploring multiple profiles in parallel to ensure that molecules are designed to solve the right problems in disease biology. It also optimizes drug candidates, deeply exploring chemical space to reveal novel mechanisms of action and deliver diverse high-quality leads.

Tempus is an AI-enabled precision medicine company that brings the power of data and artificial intelligence to healthcare. With the power of AI, Tempus accelerates the discovery of novel targets, predicts the effectiveness of treatments, identifies potentially life-saving clinical trials, and diagnoses multiple diseases earlier. Tempus' innovative technology includes ONE, an AI-enabled clinical assistant; NEXT, which identifies and closes gaps in care; LENS, which finds, accesses, and analyzes multimodal real-world data; and ALGOS, algorithmic models connected to Tempus' assays to provide additional insight.

Bionl is a no-code bioinformatics platform designed to streamline biomedical research for researchers and scientists. It offers a full workspace with features such as bioinformatics pipelines customization, GenAI for data analysis, AI-powered literature search, PDF analysis, and access to public datasets. Bionl aims to automate cloud, file system, data, and workflow management for efficient and precise analyses. The platform caters to Pharma and Biotech companies, academic researchers, and bioinformatics CROs, providing powerful tools for genetic analysis and speeding up research processes.

Genie TechBio is the world's first AI bioinformatician, offering an LLM-powered omics analysis software that operates entirely in natural language, eliminating the need for coding. Researchers can effortlessly analyze extensive datasets by engaging in a conversation with Genie, receiving recommendations for analysis pipelines, and obtaining results. The tool aims to accelerate biomedical research and empower scientists with newfound data analysis capabilities.

HoloEye.AI is a transformative AI biological intelligence company that leverages cutting-edge artificial intelligence technology to revolutionize the field of biological research. The platform offers advanced AI solutions for analyzing complex biological data, enabling researchers to gain deeper insights and accelerate scientific discoveries.

Mapmygenome is an AI-powered platform that offers DNA testing products for health, fitness, and beauty. It provides personalized insights based on genetic analysis to help individuals make informed decisions about their health, wellness, and lifestyle choices. With over 23 years of genomics experience and the latest sequencing technology, Mapmygenome aims to empower users to take proactive steps towards improving their overall well-being.

Chemprop is a PyTorch-based framework for training and evaluating message-passing neural networks (MPNNs) for molecular property prediction. Originally developed for research purposes, Chemprop offers a comprehensive set of tools and features for training models and analyzing molecular representations. The package underwent a recent major release (v2.0.0) with significant improvements and updates.

Manifold is an AI data platform designed specifically for life sciences. It offers a collaborative workbench, data science tools, AI-powered cohort exploration, batch bioinformatics, data dashboards, data engineering solutions, access control, and more. The platform aims to enable faster collaboration and research in the life sciences field by providing a comprehensive suite of tools and features. Trusted by leading institutions, Manifold helps streamline data collection, analysis, and collaboration to accelerate scientific research.

DrugCard is an AI-enabled Data Intelligence platform designed to streamline drug safety routines. It offers solutions for pharmacovigilance by providing services such as local literature screening, regulatory intelligence, adverse event database, and eCTDlight services. The platform supports multiple languages, covers medical journals from over 100 countries, and saves up to 60% of time compared to manual approaches. DrugCard aims to enhance pharmacovigilance processes by leveraging AI, automation, and traceability.

Beacon Biosignals provides an EEG neurobiomarker platform that is designed to accelerate clinical trials and enable new treatments for patients with neurological and psychiatric diseases. Their platform is powered by machine learning and a world-class clinico-EEG database, which allows them to analyze existing EEG data for insights into mechanisms, PK/PD, and patient stratification. This information can be used to guide further development efforts, optimize clinical trials, and enhance understanding of treatment efficacy.

AiCure provides a patient-centric eClinical trial management platform that enhances drug development through improved medication adherence rates, more powerful analysis and prediction of treatment response using digital biomarkers, and reduced clinical tech burden. AiCure's solutions support traditional, decentralized, or hybrid trials and offer flexibility to meet the needs of various research designs.

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques. The company's proprietary AI platform is used to identify, re-innovate, and develop potential new therapies. BioXcel Therapeutics has a pipeline of product candidates in various stages of development, including BXCL501 for agitation in dementia, BXCL701 for cocaine use disorder, and BXCL801 for acute suicidal ideation and behavior in patients with major depressive disorder.

Intelligencia AI is a leading provider of AI-powered solutions for the pharmaceutical industry. Our suite of solutions helps de-risk and enhance clinical development and decision-making. We use a combination of data, AI, and machine learning to provide insights into the probability of success for drugs across multiple therapeutic areas. Our solutions are used by many of the top global pharmaceutical companies to improve their R&D productivity and make more informed decisions.

Rationale is a cutting-edge decision-making AI tool that leverages the power of the latest GPT technology and in-context learning. It is designed to assist users in making informed decisions by providing valuable insights and recommendations based on the data provided. With its advanced algorithms and machine learning capabilities, Rationale aims to streamline the decision-making process and enhance overall efficiency.

CHAI AI is a leading conversational AI platform that focuses on building AI solutions for quant traders. The platform has secured significant funding rounds to expand its computational capabilities and talent acquisition. CHAI AI offers a range of models and techniques, such as reinforcement learning with human feedback, model blending, and direct preference optimization, to enhance user engagement and retention. The platform aims to provide users with the ability to create their own ChatAIs and offers custom GPU orchestration for efficient inference. With a strong focus on user feedback and recognition, CHAI AI continues to innovate and improve its AI models to meet the demands of a growing user base.

Cambrian Copilot is an AI tool designed for researchers and engineers to stay up-to-date with the latest machine learning research. With the ability to search over 240,000 ML papers, the tool helps users discover new research, understand complex details, and automate literature reviews. It simplifies the process of keeping track of the rapid developments in the field of machine learning.

Nexus is a Business-led Enterprise AI Platform that empowers business teams to transform their workflows into autonomous agents in a matter of days. It offers a secure, reliable, and flexible solution that enables enterprises to deploy 100x faster without involving engineering teams. Nexus provides adaptive intelligence, dynamic planning, continuous learning, and technology-agnostic intelligent automation. It allows for universal deployment, works with existing tools, and grows with businesses without increasing headcount.